Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737243 · ClinicalTrials.gov registry record · Phase 2
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 289
- Enrollment target
NCT00737243 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 289 participants.
The verdict
NCT00737243, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 289 participants
- Enrollment target
Study Summary
This is a non-randomized Phase II study. Patients determined at initial diagnosis to have a carcinoma of unknown primary site (CUP) will have their treatment selected with the use of a molecular profiling assay. The assay will be performed on paraffin-embedded tumor tissue from a biopsy specimen. Patients given specific diagnoses (e.g., lung, pancreas, colon, breast, renal cell, prostate and ovarian cancer) will receive treatment regimens of proven activity. If no specific diagnosis is made with the molecular profiling assay, empiric chemotherapy with paclitaxel, carboplatin, bevacizumab and erlotinib will be administered.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Erlotinib
- OTHER Treatment determined by physician
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00737243
The ClinicalTrials.gov registry entry for NCT00737243 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00737243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00737243 about?
NCT00737243 is a clinical study titled "Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site". This is a non-randomized Phase II study. Patients determined at initial diagnosis to have a carcinoma of unknown primary site (CUP) will have their treatment selected with the use of a molecular profiling assay. The assay will be performed on paraffin-embedded tumor tissue from a biopsy specimen. Pa...
What is the current status of trial NCT00737243?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2008-08. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00737243?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), Erlotinib (DRUG), Treatment determined by physician (OTHER).
Who is sponsoring clinical trial NCT00737243?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.